139 related articles for article (PubMed ID: 20854905)
1. A controlled release system of titanocene dichloride by electrospun fiber and its antitumor activity in vitro.
Chen P; Wu QS; Ding YP; Chu M; Huang ZM; Hu W
Eur J Pharm Biopharm; 2010 Nov; 76(3):413-20. PubMed ID: 20854905
[TBL] [Abstract][Full Text] [Related]
2. Enhanced in vitro antitumor activity of a titanocene complex encapsulated into polycaprolactone (PCL) electrospun fibers.
Stanzione M; Petillo O; Calarco A; Valarezo E; Napoli M; Longo P; Riccitiello F; Vittoria V; Peluso G
J Appl Biomater Funct Mater; 2013 Jun; 11(1):e61-70. PubMed ID: 23728536
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma.
Köpf-Maier P
Anticancer Res; 1999; 19(1A):493-504. PubMed ID: 10226588
[TBL] [Abstract][Full Text] [Related]
4. Anti-proliferative activity and mechanism of action of titanocene dichloride.
Christodoulou CV; Eliopoulos AG; Young LS; Hodgkins L; Ferry DR; Kerr DJ
Br J Cancer; 1998 Jun; 77(12):2088-97. PubMed ID: 9649119
[TBL] [Abstract][Full Text] [Related]
5. Controlled release of titanocene into the hybrid nanofibrous scaffolds to prevent the proliferation of breast cancer cells.
Laiva AL; Venugopal JR; Karuppuswamy P; Navaneethan B; Gora A; Ramakrishna S
Int J Pharm; 2015 Apr; 483(1-2):115-23. PubMed ID: 25681729
[TBL] [Abstract][Full Text] [Related]
6. Controlled release of brefeldin A from electrospun PEG-PLLA nanofibers and their in vitro antitumor activity against HepG2 cells.
Liu W; Wei J; Huo P; Lu Y; Chen Y; Wei Y
Mater Sci Eng C Mater Biol Appl; 2013 Jul; 33(5):2513-8. PubMed ID: 23623062
[TBL] [Abstract][Full Text] [Related]
7. A proposed mechanism for the inhibitory effect of the anticancer agent titanocene dichloride on tumour gelatinases and other proteolytic enzymes.
Pavlaki M; Debeli K; Triantaphyllidou IE; Klouras N; Giannopoulou E; Aletras AJ
J Biol Inorg Chem; 2009 Aug; 14(6):947-57. PubMed ID: 19390879
[TBL] [Abstract][Full Text] [Related]
8. Human tumour xenografts in nude mice: chemotherapy trials with titanocene dichloride in different dosages.
Villena-Heinsen C; Friedrich M; Ertan AK; Schmidt W
Clin Exp Obstet Gynecol; 1998; 25(1-2):5-8. PubMed ID: 9743868
[TBL] [Abstract][Full Text] [Related]
9. The addition of a pregnenolone pendant group enhances the anticancer properties of titanocene dichloride in a mcf-7 xenograft model.
Ramos G; Loperena Y; Ortiz G; Reyes F; Szeto A; Vera J; Velez J; Morales J; Morrero D; Castillo L; Dharmawardhane S; Melendez E; Washington AV
Anticancer Res; 2014 Apr; 34(4):1609-15. PubMed ID: 24692689
[TBL] [Abstract][Full Text] [Related]
10. Effects of vinorelbine and titanocene dichloride on human tumour xenografts in nude mice.
Friedrich M; Villena-Heinsen C; Farnhammer C; Schmidt W
Eur J Gynaecol Oncol; 1998; 19(4):333-7. PubMed ID: 9744720
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of Titanocene Y against freshly explanted human breast tumor cells and in xenografted MCF-7 tumors in mice.
Beckhove P; Oberschmidt O; Hanauske AR; Pampillón C; Schirrmacher V; Sweeney NJ; Strohfeldt K; Tacke M
Anticancer Drugs; 2007 Mar; 18(3):311-5. PubMed ID: 17264764
[TBL] [Abstract][Full Text] [Related]
12. Antiproliferative activity of Titanocene Y against tumor colony-forming units.
Oberschmidt O; Hanauske AR; Pampillón C; Sweeney NJ; Strohfeldt K; Tacke M
Anticancer Drugs; 2007 Mar; 18(3):317-21. PubMed ID: 17264765
[TBL] [Abstract][Full Text] [Related]
13. Human ovarian cancer xenografts in nude mice: chemotherapy trials with paclitaxel, cisplatin, vinorelbine and titanocene dichloride.
Villena-Heinsen C; Friedrich M; Ertan AK; Farnhammer C; Schmidt W
Anticancer Drugs; 1998 Jul; 9(6):557-63. PubMed ID: 9877245
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of titanocene dichloride in advanced renal-cell carcinoma.
Lümmen G; Sperling H; Luboldt H; Otto T; Rübben H
Cancer Chemother Pharmacol; 1998; 42(5):415-7. PubMed ID: 9771957
[TBL] [Abstract][Full Text] [Related]
15. In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes.
Kelter G; Sweeney NJ; Strohfeldt K; Fiebig HH; Tacke M
Anticancer Drugs; 2005 Nov; 16(10):1091-8. PubMed ID: 16222151
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity of Titanocene Y in xenografted Caki-1 tumors in mice.
Fichtner I; Pampillón C; Sweeney NJ; Strohfeldt K; Tacke M
Anticancer Drugs; 2006 Mar; 17(3):333-6. PubMed ID: 16520662
[TBL] [Abstract][Full Text] [Related]
17. Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells.
O'Connor K; Gill C; Tacke M; Rehmann FJ; Strohfeldt K; Sweeney N; Fitzpatrick JM; Watson RW
Apoptosis; 2006 Jul; 11(7):1205-14. PubMed ID: 16699961
[TBL] [Abstract][Full Text] [Related]
18. Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour.
Valadares MC; Ramos AL; Rehmann FJ; Sweeney NJ; Strohfeldt K; Tacke M; Queiroz ML
Eur J Pharmacol; 2006 Mar; 534(1-3):264-70. PubMed ID: 16513106
[TBL] [Abstract][Full Text] [Related]
19. Study of the cytotoxicity and particle action in human cancer cells of titanocene-functionalized materials with potential application against tumors.
García-Peñas A; Gómez-Ruiz S; Pérez-Quintanilla D; Paschke R; Sierra I; Prashar S; del Hierro I; Kaluđerović GN
J Inorg Biochem; 2012 Jan; 106(1):100-10. PubMed ID: 22112846
[TBL] [Abstract][Full Text] [Related]
20. Suppression of angiogenesis by the antitumor agent titanocene dichloride.
Bastaki M; Missirlis E; Klouras N; Karakiulakis G; Maragoudakis ME
Eur J Pharmacol; 1994 Jan; 251(2-3):263-9. PubMed ID: 7512041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
